This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AdaptHealth Corp. (AHCO) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AdaptHealth (AHCO) delivered earnings and revenue surprises of -93.33% and -0.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition
by Zacks Equity Research
TMO grapples with macro pressures, rising expenses and fierce competition, but bets on acquisitions to fuel recovery.
Here's Why You Should Retain AMED Stock in Your Portfolio for Now
by Zacks Equity Research
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
Here's Why You Should Retain PODD Stock in Your Portfolio Now
by Zacks Equity Research
Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.
Should You Continue to Hold Prestige Consumer Stock in Your Portfolio?
by Zacks Equity Research
PBH rides strong on e-commerce gains and brand innovations, but debt load and forex risks cast a shadow on future growth.
PEN Stock Rises Following the Launch of Ruby XL System
by Zacks Equity Research
Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
by Zacks Equity Research
OMCL stays on investors' radar due to its strong 2025 growth targets with automation and tech services, but faces margin risks from macro and competitive headwinds.
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?
by Zacks Equity Research
Thermo Fisher debuts two advanced MSs, Orbitrap Astral Zoom and Orbitrap Excedion Pro, to accelerate precision medicine and drug discovery breakthroughs.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain ICLR Stock in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about ICON, driven by its commitment to enhance clinical delivery by integrating AI and impressive strategic pacts.
LH Stock Rises Following the Expansion of Precision Oncology Portfolio
by Zacks Equity Research
Labcorp expands its precision oncology lineup with new cancer tests and a global diagnostic tool.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
PBH vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds
by Zacks Equity Research
ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
by Zacks Equity Research
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?
by Zacks Equity Research
TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.
Bruker Stock to Gain From the Launch of MOVE-T Liquid Dairy Analyzer
by Zacks Equity Research
BRKR unveils the MOVE-T analyzer to boost quality and efficiency in the dairy industry, setting new standards for precision and reliability.
Is Bio-Techne Stock the Right Pick for Your Portfolio Now?
by Zacks Equity Research
TECH is gaining ground in cell and gene therapy, and with Ella, while navigating macro hurdles. Is it the right fit for your portfolio today?
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
by Zacks Equity Research
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
Prestige Consumer Gains 35.7% in a Year: What's Driving the Stock?
by Zacks Equity Research
PBH stock jumps on the back of brand strength, e-commerce gains and smart acquisitions despite tariff and foreign exchange headwinds.
TMO Stock Set to Gain From the Launch of New Narcotic Analyzers
by Zacks Equity Research
Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.
Insulet Gains 78.5% in a Year: What's Driving the Stock?
by Zacks Equity Research
PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about HSIC, owing to the strong performance of its Henry Schein One business.
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
by Zacks Equity Research
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.